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Setting the scene
For many years, the global approach to pharmaceutical
pricing and reimbursement policies has been informed,
first and foremost, by the key differences between those
systems which relied on public sector procurement and
supply, and those which were based on reimbursement.
The first approach was considered to be the most appro-
priate for developing countries. Funding for healthcare
services was based on disbursement from the fiscus, often
exceeded by funds obtained from donors or development
partners, and supplemented by considerable out-of-pocket
payments in the form of user fees. In such systems, where
medicines were provided by the state, these were often
procured by a central medical store, and then distributed
to public sector clinics and hospitals. Pricing interventions
were limited to the application of limited competitive bid-
ding, for a list of medicines determined centrally and
severely limited. In some, but not all cases, this national
essential medicines list was informed by the WHO Model
List of Essential Medicines, updated approximately every
2 years since 1977. While procurement of generic medi-
cines was the norm, a sophisticated generic substitution
policy was often not in place. Generic prescribing was pre-
ferred, but rarely practised. Rational use of medicines was
expected to follow, almost automatically, but rarely pur-
sued with much vigour [1]. For many of these countries,
stimulating a local manufacturing industry has either been
irrelevant or of subsidiary interest. Locally relevant innova-
tion has been reliant on external funding, largely delinked
from local pharmaceutical policies.
The second approach, applied most vigorously in those
countries with national or social health insurances sys-
tem, was appropriate to systems in which the financing
of health care was separated from the provision of ser-
vices. In relation to medicines in particular, a wider range
of policy options were implemented, including a variety
of measures to promote generic medicines use, the use of
co-payments and other risk-sharing options, external
reference pricing, distribution chain price controls and
health technology assessment. In many such countries,
health policy has had to co-exist, if not seamlessly dove-
tail with industrial policies aimed at protecting local man-
ufacturing. Innovation has been almost exclusively driven,
at least after initial public support, on the protection and
exploitation of intellectual property. However, the applic-
ability of many of these pharmaceutical policies to low-
and middle-income countries has been questioned [2].
The challenge for the future is to identify a range of
pharmaceutical pricing and reimbursement policies that
are both appropriate for and supportive of countries’
attempts to introduce and entrench universal health cov-
erage. They will also need to stimulate necessary and
appropriate innovation, while ensuring a responsible and
stable pharmaceutical industry, in alignment with national
and regional industrial policies. This is a tough call, which
calls for a delicate balancing of many disparate interests, in
a way which is also patient-centred and cognisant of the
human rights at stake.
South Africa – an exemplar
South Africa has been engaged in the implementation of
a National Drug Policy since 1996, with highly publicised
challenges mounted by the pharmaceutical industry to
the initial interventions [3]. Those early interventions
included the introduction of mandatory offer of generic
substitution, a ban on all samples of medicines, a non-
discriminatory single exit price (factor gate price) for
medicines and a ban on volume discounts, a maximum
annual percentage increase in the single exit price, and a
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maximum dispensing fee for pharmacists and other dis-
pensing practitioners. The policy has aimed to achieve
‘transparency’ in the pricing of medicines, but has failed to
achieve this in relation to the logistics fee paid to wholesa-
lers and distributors by manufacturers, and included in
the single exit price. Although nationally-representative
data are elusive, it appears that the generic share by
volume (of prescriptions) is now in the mid-50 % range,
and rising very slowly. However, there are concerns that
systematic attempts have been made to circumvent the
ban on volume discounts, and to create incentives for
large buyers in the form of data fees, co-marketing fees
and other forms of off-invoice bonuses. International
benchmarking (reference pricing) has been repeatedly sig-
nalled, but as yet not implemented. The submission of
pharmacoeconomic data to justify launch prices has been
introduced, but remains voluntary. New, expensive, and
often biological, products are placing an increasing burden
on the medical schemes that serve the insured population.
Critically, the pricing and reimbursement policies listed
above apply only to the private sector, which caters for
barely 17% of the population (excluding those who pay
out of pocket) [4]. The public sector still relies on local
competitive tenders, predominantly with a single supplier
per product delivered to public sector health facilities
either via central provincial stores or directly. These pro-
ducts are identified by means of a national Essential Medi-
cines List, based on comprehensive standard treatment
guidelines. The public sector-dependent population is not
able to access medicines via the private pharmaceutical
infrastructure of community pharmacies and private hos-
pitals, but has to rely on over-stretched and poorly
resourced public sector facilities. The Minister of Health
issued a Green Paper on National Health Insurance in
2011 [5]. A final policy document has not yet been issued,
but an indication has been given that the implementation
process will take up to 14 years. Among the challenges
facing South Africa’s attempt to introduce universal health
coverage will be the need to move from a public sector
selection, procurement and supply system to one based on
reimbursement and a typical insurance-style purchaser-
provider split.
At the same time, South Africa is home to the largest
pharmaceutical manufacturing capacity on the African
continent. Local preference procurement policies underpin
the local industrial policy. Efforts to create an active phar-
maceutical ingredient manufacturing capacity are under-
way. South Africa is also trying to reform its intellectual
property system to be more critical and appropriate [6].
Perspectives for the future
If recent product launches and the prices demanded are
to be taken as a signal, and combined with the trend
towards individualised medicine, then health systems in
all countries are facing an insupportable demand for
additional resources.
There is much interest in expanding the process of
health technology assessment to low- and middle-income
countries. In part this may be achieved through greater
transparency, data sharing and the publication of models
that can be repopulated with locally-determined cost data.
However, what will be critical is the application of this
suite of methods to the selection and appropriate pricing
of the bulk of reimbursed medicines, as well as to new and
expensive medicines.
Much more attention will need to be paid to the respon-
sible use of medicines, and to systems which allow for a
reliable estimate of the value of medicines under typical
use. Whether that will enable widespread use of perfor-
mance-based pricing remains to be seen. What is critical
is that performance-based pricing must not provide a fig
leaf behind which unacceptable launch prices can be hid-
den. Reimbursement policies and processes will also need
to measured against their effects on responsible use,
and adjusted where their effects are shown to be perverse
and not in the interests of patients. Lastly, as was signalled
strongly at the onset of this conference, consideration will
need to be paid to the effect of pricing and reimbursement
policies on necessary and appropriate innovation. Standing
still is not an option, and complacency is entirely
unwarranted.
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